- Home
- DOMH vs MCRB Comparison
DOMH vs MCRB Comparison
Compare DOMH & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOMH | MCRB |
|---|---|---|
| Founded | 1967 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.3M | 71.0M |
| IPO Year | 2010 | 2015 |
Fundamental Metrics
Financial Performance| Metric | DOMH | MCRB |
|---|---|---|
| Price | $2.88 | $6.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 196.4K | 80.3K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | ★ 23.45% | N/A |
| EPS Growth | ★ 34.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $123,104,000.00 | $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 578.41 | N/A |
| 52 Week Low | $2.69 | $5.31 |
| 52 Week High | $8.40 | $29.98 |
Technical Indicators
Market Signals| Indicator | DOMH | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 40.41 | 48.82 |
| Support Level | $2.75 | $5.31 |
| Resistance Level | $3.46 | $9.53 |
| Average True Range (ATR) | 0.24 | 0.77 |
| MACD | -0.03 | 0.11 |
| Stochastic Oscillator | 3.13 | 61.04 |
Price Performance
Historical ComparisonAbout DOMH Dominari Holdings Inc.
Dominari Holdings Inc is a holding company that, through its various subsidiaries, is engaged in wealth management, investment banking, sales and trading, asset management, and insurance. In addition to capital investment, Dominari provides management support to the executive teams of its subsidiaries, helping them to operate efficiently and reduce costs under a streamlined infrastructure. The Company operates in two reportable business segments: Dominari Financial and Legacy AIkido, with the majority of revenue from Dominari Financial.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.